Kevan Herold
Affiliations: | Yale University, New Haven, CT |
Area:
Medicine and Surgery, Cell BiologyGoogle:
"Kevan Herold"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chatenoud L, Herold KC, Bach JF, et al. (2024) The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation. Cold Spring Harbor Perspectives in Medicine |
| Greenbaum CJ, Nepom GT, Wood-Heickman LK, et al. (2024) Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop. Diabetes |
| Lledó-Delgado A, Preston-Hurlburt P, Currie S, et al. (2024) Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at-risk for type 1 diabetes. The Journal of Clinical Investigation |
| Herold KC, Krischer JP. (2024) The Pathogenesis of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine |
| Quandt Z, Perdigoto A, Anderson MS, et al. (2024) Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease. Cold Spring Harbor Perspectives in Medicine |
| Jacobsen LM, Cuthbertson D, Bundy BN, et al. (2024) Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials. Diabetes Care |
| Abdel-Karim TR, Hodges JS, Herold KC, et al. (2024) Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients. Transplant International : Official Journal of the European Society For Organ Transplantation. 37: 12320 |
| Latres E, Greenbaum CJ, Oyaski ML, et al. (2024) Evidence for C-peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. Diabetes |
| Herold KC, Delong T, Perdigoto AL, et al. (2024) The immunology of type 1 diabetes. Nature Reviews. Immunology |
| Russell WE, Moore DJ, Herold KC. (2023) Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013. Diabetes Care. 46: e210-e211 |